《大行》中金:內地公募基金上季增持生物醫藥、內銀及內險 個股信達生物、三生製藥與泡泡瑪特增持最多
中金髮表報告表示,今年以來,港股市場持續活躍但又高度結構化的行業輪動行情,與異常充裕的流動性息息相關,詳細分析了港股資金面的構成與未來演變。在影響港股資金面的幾股主要力量中:除了5月至7月金管局意外投放大量資金導致港股微觀流動性極度充裕外,南向資金扮演了關鍵甚至決定性的角色,海外資金並沒有大幅迴流甚至相比3月底的配置比例還有下降。
往前看,考慮到金管局爲了守住港幣弱方仍需不斷回籠資金,美國財政第三季度有1萬億美元發債供給壓力,南向資金將扮演更爲重要的作用,證據是:1)南向資金成交佔比進一步走高至35%的高點;2)外資從數據和調查結果上,不僅沒有大舉增配,低配人數佔比反而增加。今年以來,南向淨流入規模已達到7,974.5億港元,已經接近去年全年8,078.7億港元的流入總規模。
南向資金中,根據資金屬性所體現的交易特點反推,1)主動公募基金港股持倉佔比從去年底的25.8%提升至32.5%,當前此類基金總規模約1.55萬億港元,年初至今港股配置提升規模約1,000億至1,200億港元。不過考慮到其中存在指數價格因素後(平均漲幅15%左右),年內此類基金港股淨增量約850億至1,050億港元,貢獻年初以來南向約8,000億港元流入的10%至15%左右。
中金指,內地公募基金於第二季對生物醫藥、銀行與保險等持倉提升最多,零售以及媒體娛樂明顯下滑。對比一季度,內地公募持有港股老經濟市值佔比從20.7%升至22.9%,新經濟佔比則自去年一季度以來首次下滑。細分看,生物科技,銀行與保險等板塊市值佔比提升最多。相反,可選消費零售、媒體與娛樂、汽車與零部件、半導體降幅最大。從絕對持倉水平看,媒體娛樂、製藥與生物科技以及可選消費零售等持倉最高;商業和專業服務、醫療保健設備,必需消費等持倉比例較低。相比自身歷史水平,銀行與保險等板塊已處於歷史配置高位;相反,消費者服務、能源與房地產等則處於歷史低位。
個股層面,龍頭集中度明顯下降;信達生物(01801.HK)、三生製藥(01530.HK)與泡泡瑪特(09992.HK)增持最多,阿里巴巴(09988.HK)與騰訊(00700.HK)下滑明顯。二季度內地公募基金增持醫藥與新消費,其中信達生物、三生製藥與泡泡瑪特無論是在持有基金數還是市值均增加最多;相反,阿里巴巴、騰訊與小鵬汽車(09868.HK)等則減少最多。重倉持股層面,三生製藥與快手(01024.HK)替換理想汽車(02015.HK)與中海油(00883.HK)進入前十大重倉股行列。
相比一季度,持有信達生物、三生製藥、泡泡瑪特與石藥集團(01093.HK)的基金數量上升最多。相反,持有阿里巴巴、騰訊控股、小鵬汽車以及比亞迪股份等的基金數量明顯減少。此外,重倉股集中度在二季度明顯下滑,前3大重倉股佔前100只重倉股市值30.9%,較一季度下滑8.9個百分點,前10大重倉股佔前100只重倉股市值也從一季度的64.2%下降至58.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.